Maryland Medicaid participants can now more easily access cell and gene therapies for sickle cell disease under Maryland’s participation in the federal Cell and Gene Therapy (CGT) Access Model. Participation in the CGT Access Model ensures better pricing in Maryland for high-cost medications, which helps to reduce costs and strengthen support services for patients and families who need access to these life-changing treatments. “Maryland is committed to providing innovative and accessible health solutions designed specifically for our residents,” said Maryland Department of Health Secretary Dr. Meena Seshamani. “By signing on to the CGT Access Model, we are expanding the state’s ability to provide costly, life-saving treatments that will allow Medicaid participants access to the care they need.” The CGT Access Model, administered by the Centers for Medicare & Medicaid Services (CMS), is a new federal initiative that tests whether CMS-led outcomes-based agreements (OBAs) increase Medicaid beneficiaries’ ability to access innovative treatments, improve their health outcomes, and reduce healthcare costs and burden to state Medicaid programs. Under the model, CMS negotiates outcomes-based supplemental rebate agreements with pharmaceutical manufacturers for participating Medicaid programs. The two sickle cell therapies currently available are already FDA-approved for eligible patients. Participation in the model is estimated […]
The post Maryland Joins Federal Model to Improve Access and Savings to Lifesaving Sickle Cell Treatments appeared first on Southern Maryland News Net.
Source: https://smnewsnet.comNew feed